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Introduction: Pouchitis often occurs after proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis.
It is usually deemed idiopathic and commonly responds to antibacterial therapy. To date, only a few cases of
cytomegalovirus pouchitis have been documented, and only a single report describes pouchitis in a case of
assumed primary cytomegalovirus infection.
Case presentation: A 26-year-old Caucasian woman underwent proctocolectomy and ileal pouch-anal anastomosis
for refractory ulcerative colitis and adenocarcinoma. After 28 months she developed bloody diarrhoea, abdominal pain,
fever, nausea and general malaise suggesting severe pouchitis. Antibiotic treatment reduced humoral inflammation, but
failed to resolve her fever. A pouchoscopy revealed distinct pouchitis, and cytomegalovirus infection was diagnosed from
pouch biopsies by polymerase chain reaction as well as conventional histology and immunohistochemistry. The infection
was confirmed in her blood by polymerase chain reaction and pp65 antigen test, and was clearly defined as the ‘primary’
infection by serial serological tests. Intravenous treatment with ganciclovir (10mg/kg body weight/day) led to resolution
of symptoms and negative cytomegalovirus deoxyribonucleic acid and pp65 within a few days. When symptoms
and laboratory evidence of cytomegalovirus infection recurred a few days after completing 20 days of therapy
with ganciclovir and valganciclovir, a second course of ganciclovir treatment was initiated.
Conclusions: Cytomegalovirus infection of the ileoanal pouch is an important differential diagnosis of pouchitis
even in non-immunosuppressed patients and can be treated with ganciclovir.
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Idiopathic pouchitis is a common problem after ileal
pouch-anal anastomosis (IPAA) for ulcerative colitis (UC).
It can usually be managed with antibiotics [1]. More
rarely, specific causes of pouchitis can be identified, for
example Clostridium difficile or cytomegalovirus (CMV)
infection [1-6]. CMV has infected between 40 and 100%
of the adult population [7-9]. This facultative pathogen
causes clinical illness in a small percentage of the infected,
with the greatest risk during the intrauterine period or in
immunocompromised patients [10].* Correspondence: annika.gauss@med.uni-heidelberg.de
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unless otherwise stated.CMV can aggravate pre-existing inflammatory bowel
disease (IBD), especially in immunosuppressed patients,
whereas CMV colitis has only rarely been described in
immunocompetent patients without IBD [6,11-13]. There
are few reports on CMV infection after restorative procto-
colectomy in patients with UC. A single case of a patient
with putative ‘primary’ CMV infection of the pouch was
published in 1998, and the patient was successfully treated
with ganciclovir [4]. In that case report, the definition
of primary CMV infection versus reactivation was derived
from acute symptoms, pouch biopsies with positive
immunohistochemistry and the presence of CMV im-
munoglobulin (Ig) M and G antibodies in the blood. Since
no data on antibody avidity or serological analyses from
samples taken prior to the onset of symptoms weretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is not possible. Two other case reports describe chronic
refractory pouchitis due to CMV infection [14]. Very
recently, McCurdy et al. published a retrospective case
series of seven patients with CMV infection of the ileoanal
pouch, of whom five were immunocompromised, most of
them being liver transplant patients for primary sclerosing
cholangitis. In that paper, it was not stated whether any
of the patients suffered from primary CMV infection
[6]. The only systematic analysis on the prevalence of
CMV in the ileoanal pouch detected CMV genes and
proteins in 41.6% of patients with pouchitis after proc-
tocolectomy for UC, but only in 11.2% of otherwise
comparable patients with normal pouch findings [5].
Recently, Tribonias et al. raised the question of whether
CMV in pouch mucosa might be the ‘real enemy or the
innocent bystander’ [3]. The answer may be influenced by
case-specific factors and even then difficult to determine
conclusively.
Here, we report a rare case of primary CMV infection
with pouchitis as the prevailing disease manifestation in
a patient after proctocolectomy and IPAA for UC.
Case presentation
In 2011, a 26-year-old Caucasian woman with concomi-
tant coeliac disease underwent proctocolectomy and IPAA
for refractory UC and adenocarcinoma of the colon. She
did not undergo chemotherapy. Three months later, her
ileostomy was closed. After 1 year, she suffered from acute
pouchitis, which was successfully treated with ciprofloxa-
cin and metronidazole.
She was admitted to our hospital 2.5 years after her
proctocolectomy, with severe diarrhoea, abdominal cramps,
discharge of blood, nausea, emesis, generalised malaise andTable 1 Laboratory markers and cytomegalovirus load from b








of ganciclovir (day 2
of first admission)
117 11.7 424 10,30
During first out-patient visit,
after 20 days of therapy with
ganciclovir and valganciclovir
18 9.4 222 Nega
During second hospital stay 13.7 7.7 214 2500
2 weeks after discharge from
the second hospital stay
8 8.4 249 Nega
7 weeks after discharge from
the second hospital stay
2.8 10.9 187 Nega
10 weeks after discharge
from second hospital stay
2.4 8.3 183 Nega
Abbreviations: CMV, cytomegalovirus; DNA, deoxyribonucleic acid; IgM, immunoglob
LDH, lactate dehydrogenase; n. d., not done. Normal ranges of laboratory parametechills with fever up to 38.5°C. Prior to admission, she was
not taking any medication. The physical examination
showed tachycardia (104 beats per minute) and tenderness
of her lower abdomen. Laboratory data revealed high
C-reactive protein (CRP 117mg/L: <5mg/L) and lactate
dehydrogenase (424U/L: <248U/L) and slight leucocytosis
(11.7/nL: <10.0/nL) with atypical lymphocytosis (Table 1).
Urine analysis, electrocardiography, abdominal ultrasound
and X-ray of her chest were unremarkable. The result of
the stool analysis for pathogenic bacteria and viruses was
negative, as were bacterial blood cultures. As idiopathic
pouchitis was suspected, ciprofloxacin and metronidazole
were administered. Antibiotic treatment resulted in a
decrease of CRP, but no normalisation.
A pouchoscopy on day 2 revealed pronounced pouchitis
with loss of vascularity, erythema, erosions, friability
of the mucosa and profuse fibrin exudates (Figures 1A
and 1B). Microscopic analysis showed severe erosive
inflammation with numerous granulocytes (Figure 2).
CMV polymerase chain reaction (PCR) from pouch
biopsy (available on day 5) yielded a viral burden of
7.3×107 copies/mL. A hematoxylin and eosin stain
revealed CMV inclusion bodies, while immunohisto-
chemistry showed strong nuclear staining for CMV
antigen (Figure 2). CMV deoxyribonucleic acid (DNA)
and CMV pp65 antigen in her blood were 10,300
copies/mL and 4/500,000 cells, respectively (Table 1).
On day 5, intravenous (IV) antiviral therapy with gan-
ciclovir (10mg/kg/day) was initiated. CMV pp65 in her
blood was negative after five infusions of ganciclovir
and remained so until she was discharged. Her symp-
toms resolved gradually, and CRP decreased. On day 10
of IV antiviral treatment, she was discharged in good
clinical condition. Antibiotic treatment was stopped.lood and pouch biopsies at six time points in the course
DNA in
m (copies/mL)
CMV IgM (positive or
negative); CMV IgG (titre)
CMV DNA in pouch biopsy
(copies/mL), at different sites
0 Positive; 1:8200 7.3×107
tive Positive; 1:13,000 <1000 (outside ulcer)
n. d. 83,700 (from ulcer);
1050 (outside ulcer)
tive Positive; 1:26,000 n. d.
tive n. d. 8860; 13,500; 34,900
(no ulcer)
tive n. d. 3×negative (no ulcer)
ulin M; IgG, immunoglobulin G; CRP, C-reactive protein; Ig, Immunoglobulin;
rs were: CRP <5mg/L; leukocytes 4–10/nL; LDH <248U/L.
Figure 1 Pouchoscopy findings before and after ganciclovir therapy. A and B show endoscopic photographs of the pouch one day after
admission to our hospital before treatment with ganciclovir; note the size of the biopsy tweezers in the lower left corner of A. C shows a comparable
view into the pouch 25 days after the end of the first hospital stay and after treatment with ganciclovir and valganciclovir. At that time point, the
mucosa was smooth and shiny within the whole pouch except for a single small ulceration (about 3×7mm) in the pouch corpus; D shows the view
into the pouch on day 6 of the second admission to our hospital. The ulceration, marked with an arrow, is clearly healing.
Figure 2 Microscopic findings in cytomegalovirus pouchitis. A and B show microphotographs of pouch biopsies taken before the first course of
treatment with ganciclovir (hematoxylin and eosin stain, ×40). Note the enlarged nuclei of some cells and the virus-induced eosinophilic intranuclear
and cytoplasmatic inclusions (arrows). C and D: immunohistochemistry revealing positive staining for cytomegalovirus (×40).
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day) was prescribed for another 10 days, followed by
prophylactic treatment (2×450mg/day) until the sched-
uled follow-up.
To differentiate between primary CMV infection and
reactivation, archived blood samples were analysed for
anti-CMV antibodies. CMV PCR and CMV immuno-
histochemistry were performed on previously acquired
formalin-fixed pouch specimens and the proctocolectomy
specimen. Serum CMV IgM and IgG antibodies were
detected for the first time during the patient’s hospital
stay; they were found to be negative in retrospective
analyses of archived serum specimens taken in 2009,
2010 and 2011. Avidity of CMV IgG was low, consistent
with primary CMV infection. CMV also tested negative
in the archived biopsies. Thus primary CMV infection
could be confirmed for certain.
She reported, 25 days after she was discharged from our
hospital, a sense of well-being, aside from a persistent dry
cough and increasing dyspnoea which had started shortly
after initiation of ganciclovir treatment. Examination of
her lungs yielded expiratory wheezing on both sides. A
pouchoscopy revealed normal findings except for a single
small ulcer in the pouch corpus (Figure 1C). CMV DNA
in the pouch tissue (outside the ulcer) was <1000 copies/
mL, whereas CMV pp65 and CMV DNA in her blood
tested negative (Table 1). Due to suspected pulmonary
side effects of valganciclovir, treatment was paused.
The patient reported decreased cough and dyspnoea
2 days later; because there was a primary CMV infection
in a non-immunosuppressed patient, we decided not to
resume therapy.
Ten days later, she reported increased frequency of
bowel movements and abdominal pain. CMV DNA in
her blood tested positive again, with 2500 copies/mL.
We decided to readmit her to the ward for another
16 day course of IV ganciclovir treatment and concomi-
tant treatment of her cough, which increased again after
resuming antiviral therapy. There was no evidence of lung
embolism, tuberculosis, human immunodeficiency virus
infection or infection with Mycoplasma, Pneumocystis,
Chlamydia, Legionella or Aspergillus. CMV PCR was
negative in her sputum. The results of an X-ray of her
chest and pulmonary function tests were unremarkable.
A pouchoscopy on day 6 of readmission showed a very
small healing ulcer in otherwise macroscopically and
microscopically normal mucosa (Figure 1D). A biopsy
taken from the ulcer revealed positive CMV DNA with
83,700 copies/mL; another biopsy from macroscopically
normal mucosa contained 1050 copies/mL. CMV PCR
in her blood was already negative 3 days after restart of
treatment. She was discharged in good clinical condition
with ongoing valganciclovir treatment (2×900mg/day) and
symptomatic therapy with salbutamol and codeine.At the out-patient follow-up, she had completed another
14-day course of valganciclovir (2×900mg/day) and started
prophylactic therapy (2×450mg/day) 3 days prior. She
reported being well except for a cough which was treated
with the above-indicated symptomatic medication. CMV
PCR and CMV pp65 in her blood remained negative.
Markers of humoral inflammation were nearly normal
(Table 1). Prophylactic valganciclovir therapy was con-
tinued. The next pouchoscopy 5 weeks later, with the
patient still undergoing valganciclovir prophylaxis, showed
no ulcerations. CMV DNA was detected at three different
sites of the pouch (8860 copies/mL, 13,500 copies/mL
and 34,900 copies/mL), but no inclusion bodies were
identified, and immunohistochemistry was negative. CMV
pp65 and CMV PCR in her blood were again negative.
We decided to discontinue valganciclovir prophylaxis be-
cause there were no relevant symptoms of pouchitis at
that time and, in addition to her cough, she developed
pruritus, and we found elevated alanine aminotransferase
(ALT) (216U/L: <35U/L) in her blood. In response to an
increasing number of bowel movements, we initiated oral
rifaximin therapy (2×550mg/day for 2 weeks) with the in-
tent to strengthen the mucosal barrier of the pouch and
thus to support her immune response against CMV even
without specific antiviral treatment. Her liver enzymes
normalised quickly, and her cough improved, but did not
resolve completely. Another pouchoscopy 3 weeks after
the last one revealed macroscopically normal mucosa,
negative CMV genome detection at three different sites of
the pouch, and negative CMV immunohistochemistry, as
well as no CMV inclusion bodies. During the visit at our
outpatient clinic, she complained about symptoms of
pouchitis no longer.
Discussion
We present a case of primary CMV infection of the
ileoanal pouch in a non-immunosuppressed patient after
restorative proctocolectomy for UC. To the best of our
knowledge, only one other case of primary CMV infection
manifesting as pouchitis has been published [4], although
primary infection was not clearly established there.
The route of transmission in our patient could not be
traced. The symptoms of our patient were suggestive of
a flare of idiopathic pouchitis, especially given that she
had previously experienced an episode of pouchitis
with successful antibiotic treatment. However, during
the previous episode, she had not suffered from fever,
abdominal cramps, or bloody stools. This raised the
suspicion of an additional specific pathogen, and prompted
us to test for CMV in pouch biopsies. Macroscopic
alterations of the pouch mucosa are not specific for
CMV infection. Endoscopic findings in CMV infection
of the gastrointestinal tract comprise mucosal oedema,
erythema, friability, granularity, and ulceration, and are
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as UC [14-16]. Neutrophil inflammatory exudate in the
pouch mucosa, as seen in our patient, has previously
been described as a histopathological finding of CMV
pouchitis [14]. As CMV inclusion bodies are not always
visible, CMV pouchitis can sometimes only be excluded
when suspected by the treating doctor, who has to
request CMV immunohistochemistry or CMV PCR.
Intestinal CMV infection is rare in immunocompetent
patients [17-21]. The systemic primary CMV infection
manifesting as pouchitis in our patient raised the
suspicion that there may have been some sort of local
immunosuppression in the pouch. The finding that
antibacterial therapy was already partly successful
before antiviral therapy was first initiated and that
rifaximin treatment apparently helped CMV clearance
later on, indicate that bacterial overgrowth disturbs
mucosal integrity of the pouch and thus increases the
probability of viral infection and persistence. It is
likely that in our patient, CMV infection complicated
pre-existing idiopathic pouchitis, even though it was
no reactivation, but a primary infection.
We suggest that in our patient, CMV was not just an
‘innocent bystander’, but a potentially relevant ‘enemy’.
The initial decision to begin antiviral treatment was
based on the general malaise of the patient, the relatively
high viral burden in the biopsies, and positive CMV
DNA and pp65 in her blood. We chose to treat the
infection for 10 days with IV ganciclovir and switched
to a therapeutic dose of oral valganciclovir for another
10 days. This approach is in line with the treatment
recommended in national and international UC guide-
lines [22,23]. Usually, a 2- to 3-week course of ganciclovir
alone or ganciclovir and subsequent valganciclovir is
recommended. There are no consistent recommendations
on the need and duration of post-therapy intake of valgan-
ciclovir, especially not in cases of primary CMV infection
in immunocompetent patients. Of interest, in our patient,
the ileoanal pouch was clearly the main reservoir of CMV.
Obviously, CMV infection can persist much longer in the
intestinal mucosa than suggested from blood results.
Because of this, the treatment duration of 2 to 3 weeks
may be too short and, as suggested by McCurdy et al.
[6], not only blood tests, but also a repeat endoscopic
examination should be considered to confirm CMV
eradication and to assess mucosal healing. In our patient,
we feel that the initial treatment duration was too short.
Of course, the situation in our patient was peculiar, as she
developed relevant side effects of the antiviral therapy.
But the time span between the first diagnosis of CMV
pouchitis and the last pouchoscopy – in which CMV
could not be detected in the pouch mucosa – was
140 days, despite the patient receiving antiviral treatment
or prophylaxis during much of this period. In retrospect,it might have been helpful if we had adhered to anti-
biotic treatment with ciprofloxacin and metronidazole
in addition to antiviral treatment following discharge
from the first hospital stay, e. g. for 4 weeks.
Also, our case reveals once more the importance of
the selection of the site of the mucosa from which to
take a specimen for CMV DNA analysis because samples
taken from ulcers contain significantly more CMV DNA
than those taken from intact mucosa.
Conclusions
In conclusion, CMV should be considered a cause of
pouchitis, given the availability of an efficient antiviral
treatment, especially in patients suffering from fever.
CMV infection of the pouch might be a complication of
pre-existing idiopathic pouchitis, so that additional anti-
bacterial treatment seems to be helpful. A prospective
study to systematically analyse the role of CMV in pou-
chitis is worthwhile.
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